Concepedia

Richard Ventura

RV

9

Publications

2.1K

Citations

9

H-Index

2000

Active since

Affiliations

NGM Biopharmaceuticals (United States)(Current)

Exelixis (United States)

Pacific Biosciences (United States)

Harvard University

Richard Ventura is an author at NGM Biopharmaceuticals (United States) specializing in medicine, pharmacology, and liver physiology.

ORCID

Top concepts

Publications per year

2000–2021

9

Publications

9

A complementary transposon tool kit for Drosophila melanogaster using P and piggyBac

Stephen T. Thibault, Matthew A. Singer, W Y Miyazaki et al. · Nature Genetics · 2004 · 843 citations · Full text

, , +7

Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression

Richard Ventura, Kasia Mordec, Joanna Waszczuk et al. · EBioMedicine · 2015 · 288 citations · Full text

Lava Lamp, a Novel Peripheral Golgi Protein, Is Required for <i>Drosophila melanogaster</i> Cellularization

John C. Sisson, Christine M. Field, Richard Ventura et al. · The Journal of Cell Biology · 2000 · 279 citations · Full text

Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice

Rowena Suriben, Michael Chen, Jared Higbee et al. · Nature Medicine · 2020 · 273 citations

, , +6

FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression

Timothy S. Heuer, Richard Ventura, Kasia Mordec et al. · EBioMedicine · 2016 · 128 citations · Full text

Rows per page

1–5 of 9